Merck submitted a nonbinding offer for the smaller biotech earlier in the year, according to a media report citing people ...

The bear market induced by the Federal Reserve’s monetary tightening officially ended in 2023, but it seems no one remembered ...

For investors still seeking companiies with attractive long-term prospects, let's consider two in the biotech industry: ...

Forget the hyper-volatile, high-profile stock names. In this environment, lesser-known and less-exciting stocks are apt to ...

Regencell's stock soared 17,000% fueled by speculation, despite no revenue or clinical progress. Read why I think the RGC ...

French drugmaker Sanofi said Monday it has agreed to acquire Blueprint Medicines for $9.5 billion, sending shares of the ...

Barreling toward the loss of exclusivity on its blockbuster oncology therapy Keytruda, Merck & Co. has reportedly offered $3 ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Ailsa Craig and Marek Poszepczynski, portfolio managers at the International Biotechnology Trust, tell MoneyWeek where they’d ...

Intellia Therapeutics’ stock may have taken a hit in the wake of details of a grade 4 adverse event in a phase 3 trial, but ...

Biotech stocks lagged the broader market in 2023 and 2024, and the SDPR S&P Biotech ETF (NYSE: XBI) is trading at the same level as in 2017. While biotech stocks soared during the COVID-19 ...